Professional Role and Expertise
Dan Gutfinger, MD, PhD, is a Cardiothoracic Surgeon currently affiliated with Abbott, where he focuses on medical device development and clinical research specifically in the arena of structural heart disease. His professional profile, as indicated on LinkedIn and affiliated institutional pages, underscores his dual expertise in surgery and medical innovation, bridging clinical practice and device technology.
Educational Background
Dr. Gutfinger completed his academic training entirely at the University of California, Irvine, attaining a Bachelor of Science in 1983, Master of Science in 1986, and PhD in 1990. His extensive formal education supports a deep foundation in biomedical sciences and clinical medicine.
Research and Development Contributions
Dr. Gutfinger's research output and patent activity concentrate on cardiac surgery and implantable medical devices. He is associated with innovations such as a system and method for calibrating cardiac pressure measurements via implantable devices, demonstrating his role in advancing cardiovascular monitoring technologies.
He has notable contributions regarding transcatheter device therapies, including studies on the Amplatzer Piccolo Occluder for patent ductus arteriosus (PDA) closure in fragile pediatric populations. A prospective multicenter follow-up study he co-authored reports high closure success rates (>95% survival at 3 years) with low complication incidences, highlighting his involvement in evaluating long-term device efficacy and safety.
Published research also addresses the persistence of surgical PDA ligation amid increasing transcatheter interventions, where Dr. Gutfinger explores clinical and anatomical factors affecting device applicability in premature infants with cardiac conditions.
Clinical and Industry Impact
In his leadership capacity as a Medical Director at Abbott, Dr. Gutfinger contributes to the strategic development and clinical validation of structural heart products. His involvement is cited in forums such as the Society of Thoracic Surgeons' leadership orientations and registry data utilization for FDA surveillance, indicating a role in regulatory and quality assurance processes.
His clinical insights have informed real-world outcomes of surgical aortic valve replacement devices (e.g., Trifecta valve), reflecting an integration of clinical data and industry development to optimize patient treatments.
Publications and Scholarly Influence
On Google Scholar and ResearchGate, Dr. Gutfinger is credited with at least 11 research works, including topics such as transcatheter atrioventricular valve repair/replacement in pediatric patients, demonstrating a specific focus on minimally invasive cardiac therapies for complex cases.
His published works often intersect clinical cardiology, pediatric interventions, and device engineering, underlining expertise valuable to evolving heart failure therapies and interventional cardiology.
Key actionable insights:
- Dr. Gutfinger embodies a blend of clinical surgical expertise and device innovation, positioning him as a pivotal stakeholder in Abbott’s structural heart portfolio.
- His academic rigor (PhD + MD) and sustained research leadership provide a strong foundation for evidence-driven product development.
- His focus on pediatric and congenital heart conditions via device therapy aligns with Abbott’s strategic growth areas in minimally invasive cardiovascular solutions.
- Involvement with FDA and registry-driven outcomes suggests familiarity with regulatory pathways and clinical trial data interpretation, critical for device adoption and market expansion.
This profile highlights Dr. Gutfinger’s authoritative position in both clinical practice and the medical device industry, with a strong orientation towards innovation in structural heart disease management.
